> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves 2nd Remicade Biosimilar Product
- URL: https://www.fdaweb.com/fda-approves-2nd-remicade-biosimilar-product/
- Published: 2017-04-24T12:00:00.000Z
- Updated: 2026-09-14T22:19:24.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5138523

FDA has approved a Samsung Bioepis abbreviated BLA for Renflexis (infliximab-abda), a biosimilar of Janssen’s Remicade, indicated for treating Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. This is the second biosimilar referencing Remicade to receive approval; Celltrion and Hospira gained approval for Inflectra last year.